Skip to content

Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)

Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02515539
Enrollment
0
Registered
2015-08-04
Start date
2015-08-31
Completion date
2021-07-31
Last updated
2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Heart Disease, Heart Valve Disease, Mitral Insufficiency

Keywords

Transcatheter Mitral Valve Replacement, Mitral Regurgitation, Mitral Insufficiency, Transapical, Transfemoral

Brief summary

The purpose of the study is to generate early US feasibility data of the CardiAQ™ Transcatheter Mitral Valve Implant System. The study will enroll patients with moderate to severe mitral valve regurgitation who are considered high risk for mortality and morbidity from conventional open-heart surgery.

Detailed description

Early feasibility study - multi-center, prospective, single-arm, and non-randomized study without concurrent or historical controls. The primary objective of the study is to generate early feasibility data for the CardiAQ™ Transcatheter Mitral Valve Implant System with the Transfemoral and Transapical Delivery Systems for the treatment of moderate to severe mitral valve regurgitation in patients who are considered high risk for mortality and morbidity from conventional open-heart surgery. The secondary objectives of the study are to evaluate the long-term safety of the device and the effects of the device on performance, functional, quality of life parameters, and technical, device, procedural, and individual patient successes. The study is to be performed at a maximum of 5 investigational sites in the US.

Interventions

DEVICECardiAQ TMVI System (Transapical & Transfemoral DS)

CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System

Sponsors

Edwards Lifesciences
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * NYHA Classification ≥ III * Left Ventricular Ejection Fraction ≥ 30% * Mitral Regurgitation ≥ Grade 3+ * Subject meets anatomical and eligibility criteria for the investigational device

Exclusion criteria

* See Protocol

Design outcomes

Primary

MeasureTime frame
Composite Major Adverse Event Rate30-Day

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026